Pharmacogenomic Effect/ADR for Warfarin (DBSNPE000253)

Identifier
DBSNPE000253
Drug
Warfarin (DB00682)
Interacting Gene/Enzyme
Phylloquinone omega-hydroxylase CYP4F2
Gene Name
CYP4F2
UniProt ID
P78329
Defining Change(s)
T Allele, homozygousrs2108622
Allele Name
Not Available
Genotype(s)
(T;T)
Type(s)
Effect Directly Studied
Groups
Not Available
Description
Patients with this genotype in CP4F2 may require higer doses of warfarin to attain therapeutic anticoagulant activity.
References
  1. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M: Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017 Feb 15. doi: 10.1002/cpt.668. [Article]